MHRA approach to medicines using non-animal methods

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the reduction of animal testing in medicinal product development, aligning with the UK’s policy to phase out animal use. Grounded in the "3Rs" principles (Replacement, Reduction, and Refinement), the regulatory framework follows International Council for Harmonisation (ICH) standards while allowing scientifically justified exceptions. The guidance addresses the historical issue that animal models do not always accurately predict human outcomes and promotes the transition toward non-animal-based testing methods. Required actions for developers include providing robust scientific justifications for omitting animal studies and ensuring that alternative data—such as in silico models or microphysiological systems—demonstrate safety for the proposed clinical context. For generic and biosimilar products, the MHRA explicitly discourages animal testing. Developers must ensure all safety studies remain compliant with OECD Good Laboratory Practice (GLP) standards. Additionally, the MHRA will establish a new mechanism by late 2026 to review non-clinical data (Module 4) early in the application process for products developed entirely without animal testing, helping to de-risk innovative development strategies while maintaining high safety standards for UK patients.